SCHEMBL16234953

SCHEMBL16234953

COC(=O)c1cnc(NS(=O)(=O)c2cc(Cl)sc2Cl)c(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALPL P05186 6/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ S100A9 P06702 2/20 0.44
▸ CDK1 P06493 1/20 0.43
▸ CCNB1 P14635 1/20 0.43
▸ CCNA2 P20248 1/20 0.43
▸ CCND1 P24385 1/20 0.43
▸ CDK2 P24941 1/20 0.43
▸ CDK7 P50613 1/20 0.43
▸ CCNH P51946 1/20 0.43
▸ CCNA1 P78396 1/20 0.43
▸ CDK6 Q00534 1/20 0.43
▸ CCR4 P51679 2/20 0.42
▸ PFKFB3 Q16875 1/20 0.40
▸ PIK3C3 Q8NEB9 1/20 0.40
▸ ACLY P53396 3/20 0.39
▸ LMNA P02545 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ CMA1 P23946 1/20 0.38
▸ P2RY12 Q9H244 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16235330 0.88 TDP1 (0.46) ALPLTDP1S100A9CDK1CCNB1
SCHEMBL17472686 0.83 CCR4 (0.47) ALPLTDP1S100A9CDK1CCNB1
SCHEMBL28163264 0.83 S100A9 (0.46) TDP1S100A9CDK1CCNB1CCNA2
SCHEMBL28053283 0.83 S100A9 (0.42) ALPLTDP1S100A9CDK1CCNB1
SCHEMBL28053284 0.82 TDP1 (0.43) TDP1S100A9CDK1CCNB1CCNA2
SCHEMBL16235224 0.76 S100A9 (0.49) TDP1S100A9CDK1CCNB1CCNA2
SCHEMBL16235104 0.75 CCR4 (0.51) ALPLTDP1CCR4ACLYLMNA
SCHEMBL16235327 0.74 TDP1 (0.58) TDP1S100A9CDK1CCNB1CCNA2
SCHEMBL17698924 0.73 TSHR (0.43) ALPLTDP1CDK1CCNB1CCNA2
SCHEMBL16235585 0.71 S100A9 (0.53) TDP1S100A9CDK1CCNB1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10125125-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-11-13 — — US disclosed
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2018-06-07 — — US disclosed
US-9873687-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-01-23 — — US disclosed
US-20160115158-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-04-28 — — US disclosed
EP-2925743-B1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-02-03 — — EP disclosed
EP-2925743-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS Active Biotech AB (SE) 2015-10-07 — — EP disclosed
WO-2014184234-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2014-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10125125-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors S100A9, S100B, S100A10 ALPL 2152/4885TDP1 3192/4885S100A9 1/4885
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS S100A9, S100B, S100A10 ALPL 2152/4885TDP1 3192/4885S100A9 1/4885
US-20160115158-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS S100A9, S100A4, S100B ALPL 2767/4885TDP1 2604/4885S100A9 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback